Assessing the performance of amorphous solid dispersions

The characterization and performance of stable amorphous solid dispersion systems were evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution and bioavailability from various systems containing polymers. The results from these studies were broadly placed into th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2012-04, Vol.101 (4), p.1355-1377
Hauptverfasser: Newman, Ann, Knipp, Gregory, Zografi, George
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1377
container_issue 4
container_start_page 1355
container_title Journal of pharmaceutical sciences
container_volume 101
creator Newman, Ann
Knipp, Gregory
Zografi, George
description The characterization and performance of stable amorphous solid dispersion systems were evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution and bioavailability from various systems containing polymers. The results from these studies were broadly placed into three categories: amorphous dispersions that improved bioavailability (∼82% of the cases), amorphous dispersions possessing lower bioavailability than the reference material (∼8% of the cases), and amorphous dispersions demonstrating similar bioavailabilities as the reference material (∼10% of the cases). A comparative analysis of these studies revealed several in vitro and in vivo variables that could have influenced the results. The in vitro factors compared primarily centered on dissolution testing and equipment, content and amount of dissolution media, sink or nonsink conditions, agitation rates, media pH, dissolution characteristics of the polymer, and dispersion particle size. The in vivo factors included reference materials used for bioavailability comparisons, animal species utilized, fasting versus fed conditions, and regional differences in gastrointestinal (GI) content and volume. On the basis of these considerations, a number of recommendations were made on issues ranging from the assessment of physical stability of API–polymer dispersions to in vivo GI physiological factors that require consideration in the performance evaluation of these systems. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association
doi_str_mv 10.1002/jps.23031
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_923951438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915316324</els_id><sourcerecordid>923951438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5001-58e919212fe6df82e3ef34068eb2d76527fcba40fcbbfb7d7be21de187f9eb933</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhi3UCrbAoX-gitQD6iHgjziOj2hLt6WIDwHiaCXxuHhJ4tSz25Z_X9MAhwou48M88-rVY0LeM7rPKOUHyxH3uaCCbZAZk5zmJWXqDZmlHc-FLPQWeYe4pJSWVMpNssU5Z6IoqxmpDhEB0Q8_stUtZCNEF2JfDy1kwWV1H-J4G9aYYei8zazHRKAPA-6Qt67uEHYf321y_eXoav41PzlbfJsfnuStpJTlsgLNNGfcQWldxUGAEwUtK2i4VaXkyrVNXdA0G9coqxrgzAKrlNPQaCG2yd6UO8bwcw24Mr3HFrquHiAVM5oLLVkhqkR-_I9chnUcUjnDJFNCF0I85H2aqDYGxAjOjNH3dbw3jJoHmybZNP9sJvbDY-K66cE-k0_6EnAwAb99B_evJ5nj88unyHy68LiCP88XdbwzpRJKmpvThVEX-vj75_mVWSReTDwkx788RIOth_Q91kdoV8YG_0Lxv-EKnrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1517394333</pqid></control><display><type>article</type><title>Assessing the performance of amorphous solid dispersions</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Newman, Ann ; Knipp, Gregory ; Zografi, George</creator><creatorcontrib>Newman, Ann ; Knipp, Gregory ; Zografi, George</creatorcontrib><description>The characterization and performance of stable amorphous solid dispersion systems were evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution and bioavailability from various systems containing polymers. The results from these studies were broadly placed into three categories: amorphous dispersions that improved bioavailability (∼82% of the cases), amorphous dispersions possessing lower bioavailability than the reference material (∼8% of the cases), and amorphous dispersions demonstrating similar bioavailabilities as the reference material (∼10% of the cases). A comparative analysis of these studies revealed several in vitro and in vivo variables that could have influenced the results. The in vitro factors compared primarily centered on dissolution testing and equipment, content and amount of dissolution media, sink or nonsink conditions, agitation rates, media pH, dissolution characteristics of the polymer, and dispersion particle size. The in vivo factors included reference materials used for bioavailability comparisons, animal species utilized, fasting versus fed conditions, and regional differences in gastrointestinal (GI) content and volume. On the basis of these considerations, a number of recommendations were made on issues ranging from the assessment of physical stability of API–polymer dispersions to in vivo GI physiological factors that require consideration in the performance evaluation of these systems. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.23031</identifier><identifier>PMID: 22213468</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Hoboken: Elsevier Inc</publisher><subject>absorption ; amorphous ; Animals ; bioavailability ; Biological Availability ; dissolution ; Humans ; Hydrogen-Ion Concentration ; in vitro–in vivo correlation (IVIVC) ; Particle Size ; polymers ; Polymers - chemistry ; Polymers - pharmacokinetics ; solid dispersion ; solid dosage form ; Solubility ; stabilization</subject><ispartof>Journal of pharmaceutical sciences, 2012-04, Vol.101 (4), p.1355-1377</ispartof><rights>2012 Wiley Periodicals, Inc.</rights><rights>Copyright © 2011 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5001-58e919212fe6df82e3ef34068eb2d76527fcba40fcbbfb7d7be21de187f9eb933</citedby><cites>FETCH-LOGICAL-c5001-58e919212fe6df82e3ef34068eb2d76527fcba40fcbbfb7d7be21de187f9eb933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.23031$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.23031$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22213468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newman, Ann</creatorcontrib><creatorcontrib>Knipp, Gregory</creatorcontrib><creatorcontrib>Zografi, George</creatorcontrib><title>Assessing the performance of amorphous solid dispersions</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>The characterization and performance of stable amorphous solid dispersion systems were evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution and bioavailability from various systems containing polymers. The results from these studies were broadly placed into three categories: amorphous dispersions that improved bioavailability (∼82% of the cases), amorphous dispersions possessing lower bioavailability than the reference material (∼8% of the cases), and amorphous dispersions demonstrating similar bioavailabilities as the reference material (∼10% of the cases). A comparative analysis of these studies revealed several in vitro and in vivo variables that could have influenced the results. The in vitro factors compared primarily centered on dissolution testing and equipment, content and amount of dissolution media, sink or nonsink conditions, agitation rates, media pH, dissolution characteristics of the polymer, and dispersion particle size. The in vivo factors included reference materials used for bioavailability comparisons, animal species utilized, fasting versus fed conditions, and regional differences in gastrointestinal (GI) content and volume. On the basis of these considerations, a number of recommendations were made on issues ranging from the assessment of physical stability of API–polymer dispersions to in vivo GI physiological factors that require consideration in the performance evaluation of these systems. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association</description><subject>absorption</subject><subject>amorphous</subject><subject>Animals</subject><subject>bioavailability</subject><subject>Biological Availability</subject><subject>dissolution</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>in vitro–in vivo correlation (IVIVC)</subject><subject>Particle Size</subject><subject>polymers</subject><subject>Polymers - chemistry</subject><subject>Polymers - pharmacokinetics</subject><subject>solid dispersion</subject><subject>solid dosage form</subject><subject>Solubility</subject><subject>stabilization</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1P3DAQhi3UCrbAoX-gitQD6iHgjziOj2hLt6WIDwHiaCXxuHhJ4tSz25Z_X9MAhwou48M88-rVY0LeM7rPKOUHyxH3uaCCbZAZk5zmJWXqDZmlHc-FLPQWeYe4pJSWVMpNssU5Z6IoqxmpDhEB0Q8_stUtZCNEF2JfDy1kwWV1H-J4G9aYYei8zazHRKAPA-6Qt67uEHYf321y_eXoav41PzlbfJsfnuStpJTlsgLNNGfcQWldxUGAEwUtK2i4VaXkyrVNXdA0G9coqxrgzAKrlNPQaCG2yd6UO8bwcw24Mr3HFrquHiAVM5oLLVkhqkR-_I9chnUcUjnDJFNCF0I85H2aqDYGxAjOjNH3dbw3jJoHmybZNP9sJvbDY-K66cE-k0_6EnAwAb99B_evJ5nj88unyHy68LiCP88XdbwzpRJKmpvThVEX-vj75_mVWSReTDwkx788RIOth_Q91kdoV8YG_0Lxv-EKnrA</recordid><startdate>201204</startdate><enddate>201204</enddate><creator>Newman, Ann</creator><creator>Knipp, Gregory</creator><creator>Zografi, George</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201204</creationdate><title>Assessing the performance of amorphous solid dispersions</title><author>Newman, Ann ; Knipp, Gregory ; Zografi, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5001-58e919212fe6df82e3ef34068eb2d76527fcba40fcbbfb7d7be21de187f9eb933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>absorption</topic><topic>amorphous</topic><topic>Animals</topic><topic>bioavailability</topic><topic>Biological Availability</topic><topic>dissolution</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>in vitro–in vivo correlation (IVIVC)</topic><topic>Particle Size</topic><topic>polymers</topic><topic>Polymers - chemistry</topic><topic>Polymers - pharmacokinetics</topic><topic>solid dispersion</topic><topic>solid dosage form</topic><topic>Solubility</topic><topic>stabilization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newman, Ann</creatorcontrib><creatorcontrib>Knipp, Gregory</creatorcontrib><creatorcontrib>Zografi, George</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newman, Ann</au><au>Knipp, Gregory</au><au>Zografi, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessing the performance of amorphous solid dispersions</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>2012-04</date><risdate>2012</risdate><volume>101</volume><issue>4</issue><spage>1355</spage><epage>1377</epage><pages>1355-1377</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>The characterization and performance of stable amorphous solid dispersion systems were evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution and bioavailability from various systems containing polymers. The results from these studies were broadly placed into three categories: amorphous dispersions that improved bioavailability (∼82% of the cases), amorphous dispersions possessing lower bioavailability than the reference material (∼8% of the cases), and amorphous dispersions demonstrating similar bioavailabilities as the reference material (∼10% of the cases). A comparative analysis of these studies revealed several in vitro and in vivo variables that could have influenced the results. The in vitro factors compared primarily centered on dissolution testing and equipment, content and amount of dissolution media, sink or nonsink conditions, agitation rates, media pH, dissolution characteristics of the polymer, and dispersion particle size. The in vivo factors included reference materials used for bioavailability comparisons, animal species utilized, fasting versus fed conditions, and regional differences in gastrointestinal (GI) content and volume. On the basis of these considerations, a number of recommendations were made on issues ranging from the assessment of physical stability of API–polymer dispersions to in vivo GI physiological factors that require consideration in the performance evaluation of these systems. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association</abstract><cop>Hoboken</cop><pub>Elsevier Inc</pub><pmid>22213468</pmid><doi>10.1002/jps.23031</doi><tpages>23</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2012-04, Vol.101 (4), p.1355-1377
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_923951438
source MEDLINE; Wiley Online Library; Alma/SFX Local Collection
subjects absorption
amorphous
Animals
bioavailability
Biological Availability
dissolution
Humans
Hydrogen-Ion Concentration
in vitro–in vivo correlation (IVIVC)
Particle Size
polymers
Polymers - chemistry
Polymers - pharmacokinetics
solid dispersion
solid dosage form
Solubility
stabilization
title Assessing the performance of amorphous solid dispersions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A07%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessing%20the%20performance%20of%20amorphous%20solid%20dispersions&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Newman,%20Ann&rft.date=2012-04&rft.volume=101&rft.issue=4&rft.spage=1355&rft.epage=1377&rft.pages=1355-1377&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.23031&rft_dat=%3Cproquest_cross%3E923951438%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1517394333&rft_id=info:pmid/22213468&rft_els_id=S0022354915316324&rfr_iscdi=true